Athersys Inc. (NASDAQ:ATHX) traded at a new 52-week low today of $1.36. This new low was reached on below average trading volume as 493,000 shares traded hands, while the average 30-day volume is approximately 2.3 million shares.
Athersys Inc. (NASDAQ:ATHX) is currently priced 6.0% above its average consensus analyst price target of $1.30.
Athersys Inc is a biotechnology company. It is focused on developing novel and proprietary therapies in the areas where there is a unmet medical need, particularly in the regenerative medicine area. The firm’s main product is Multistem cell therapy. Its current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders and certain pulmonary conditions. Its revenue has been derived from corporate collaborations, license agreements, and government grants.
Athersys Inc. share prices have moved between a 52-week high of $3.21 and the current low of $1.36 and are currently at $1.39 per share.
Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts
To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected
About InvestorBrandNetwork (IBN)
InvestorBrandNetwork (IBN) consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign.
For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer